These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 20425851)
21. Changes in structural lung disease in cystic fibrosis children over 4 years as evaluated by high-resolution computed tomography. Carpio C; Albi G; Rayón-Aledo JC; Álvarez-Sala R; Girón R; Prados C; Caballero P Eur Radiol; 2015 Dec; 25(12):3577-85. PubMed ID: 25929944 [TBL] [Abstract][Full Text] [Related]
22. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274 [TBL] [Abstract][Full Text] [Related]
23. Structural and functional lung disease in primary ciliary dyskinesia. Santamaria F; Montella S; Tiddens HAWM; Guidi G; Casotti V; Maglione M; de Jong PA Chest; 2008 Aug; 134(2):351-357. PubMed ID: 18403663 [TBL] [Abstract][Full Text] [Related]
24. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. Rubin BK J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):71-6. PubMed ID: 18518833 [TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. Strateva T; Petrova G; Mitov I J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744 [TBL] [Abstract][Full Text] [Related]
26. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients]. Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499 [TBL] [Abstract][Full Text] [Related]
27. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266 [TBL] [Abstract][Full Text] [Related]
28. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Orriols R; Hernando R; Ferrer A; Terradas S; Montoro B Respiration; 2015; 90(4):299-305. PubMed ID: 26340658 [TBL] [Abstract][Full Text] [Related]
29. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD; Elborn JS Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [TBL] [Abstract][Full Text] [Related]
30. Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. Rothman KJ; Wentworth CE Epidemiology; 2003 Jan; 14(1):55-9. PubMed ID: 12500046 [TBL] [Abstract][Full Text] [Related]
31. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831 [TBL] [Abstract][Full Text] [Related]
32. Relationship between sputum inflammatory markers, lung function, and lung pathology on high-resolution computed tomography in children with cystic fibrosis. Dakin CJ; Pereira JK; Henry RL; Wang H; Morton JR Pediatr Pulmonol; 2002 Jun; 33(6):475-82. PubMed ID: 12001282 [TBL] [Abstract][Full Text] [Related]
33. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Robinson TE; Leung AN; Northway WH; Blankenberg FG; Bloch DA; Oehlert JW; Al-Dabbagh H; Hubli S; Moss RB J Pediatr; 2001 Apr; 138(4):553-9. PubMed ID: 11295720 [TBL] [Abstract][Full Text] [Related]
34. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
35. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282 [TBL] [Abstract][Full Text] [Related]
36. Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Couch LA Chest; 2001 Sep; 120(3 Suppl):114S-117S. PubMed ID: 11555565 [TBL] [Abstract][Full Text] [Related]
37. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656 [TBL] [Abstract][Full Text] [Related]
38. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Robinson TE; Goris ML; Zhu HJ; Chen X; Bhise P; Sheikh F; Moss RB Chest; 2005 Oct; 128(4):2327-35. PubMed ID: 16236891 [TBL] [Abstract][Full Text] [Related]
39. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Wiesemann HG; Steinkamp G; Ratjen F; Bauernfeind A; Przyklenk B; Döring G; von der Hardt H Pediatr Pulmonol; 1998 Feb; 25(2):88-92. PubMed ID: 9516091 [TBL] [Abstract][Full Text] [Related]
40. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Gibson RL; Emerson J; Mayer-Hamblett N; Burns JL; McNamara S; Accurso FJ; Konstan MW; Chatfield BA; Retsch-Bogart G; Waltz DA; Acton J; Zeitlin P; Hiatt P; Moss R; Williams J; Ramsey BW Pediatr Pulmonol; 2007 Jul; 42(7):610-23. PubMed ID: 17534969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]